Noel Mueller
Concepts (475)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Gastrointestinal Microbiome | 25 | 2025 | 635 | 9.160 |
Why?
| Microbiota | 15 | 2024 | 724 | 5.140 |
Why?
| Cesarean Section | 13 | 2023 | 180 | 5.020 |
Why?
| Delivery, Obstetric | 10 | 2022 | 133 | 4.130 |
Why?
| Fatty Acids, Volatile | 8 | 2025 | 57 | 3.500 |
Why?
| Pre-Eclampsia | 7 | 2025 | 183 | 3.300 |
Why?
| Adiposity | 11 | 2024 | 505 | 2.990 |
Why?
| Pediatric Obesity | 13 | 2025 | 568 | 2.820 |
Why?
| Trace Elements | 4 | 2021 | 46 | 2.790 |
Why?
| Body Mass Index | 30 | 2025 | 2250 | 2.690 |
Why?
| Menarche | 7 | 2023 | 58 | 2.570 |
Why?
| Hypertension | 11 | 2024 | 1237 | 2.320 |
Why?
| Pregnancy | 41 | 2025 | 6256 | 2.300 |
Why?
| Feces | 11 | 2024 | 430 | 2.210 |
Why?
| Blood Pressure | 16 | 2025 | 1746 | 2.170 |
Why?
| Prenatal Exposure Delayed Effects | 10 | 2024 | 551 | 2.110 |
Why?
| Metals, Heavy | 3 | 2021 | 28 | 2.090 |
Why?
| Mothers | 13 | 2023 | 723 | 1.850 |
Why?
| Vagina | 7 | 2024 | 173 | 1.800 |
Why?
| Female | 104 | 2025 | 68274 | 1.630 |
Why?
| Diabetes Mellitus, Type 2 | 13 | 2022 | 2421 | 1.550 |
Why?
| Metformin | 5 | 2022 | 307 | 1.540 |
Why?
| Dietary Fiber | 3 | 2023 | 51 | 1.540 |
Why?
| Infant, Newborn | 23 | 2025 | 5707 | 1.480 |
Why?
| Dietary Approaches To Stop Hypertension | 3 | 2020 | 11 | 1.470 |
Why?
| Breast Feeding | 4 | 2025 | 424 | 1.450 |
Why?
| Milk, Human | 2 | 2024 | 145 | 1.410 |
Why?
| Fetal Blood | 4 | 2022 | 315 | 1.410 |
Why?
| Humans | 132 | 2025 | 129078 | 1.410 |
Why?
| Carbonated Beverages | 3 | 2015 | 16 | 1.340 |
Why?
| Infant | 27 | 2025 | 8997 | 1.310 |
Why?
| Dietary Carbohydrates | 3 | 2021 | 151 | 1.300 |
Why?
| Premature Birth | 2 | 2023 | 313 | 1.250 |
Why?
| Dietary Proteins | 2 | 2020 | 131 | 1.230 |
Why?
| Obesity | 15 | 2022 | 2847 | 1.170 |
Why?
| Cardiovascular Diseases | 9 | 2022 | 2016 | 1.160 |
Why?
| Prospective Studies | 23 | 2025 | 7070 | 1.150 |
Why?
| Longevity | 2 | 2019 | 150 | 1.150 |
Why?
| Diet | 15 | 2024 | 1205 | 1.060 |
Why?
| Metabolome | 3 | 2024 | 316 | 1.050 |
Why?
| Methylamines | 2 | 2024 | 31 | 1.050 |
Why?
| Adult | 56 | 2024 | 35423 | 1.040 |
Why?
| Child | 36 | 2025 | 20860 | 1.030 |
Why?
| Male | 72 | 2025 | 63248 | 1.030 |
Why?
| Non-Nutritive Sweeteners | 2 | 2015 | 5 | 1.010 |
Why?
| Plasminogen Activator Inhibitor 1 | 1 | 2024 | 86 | 0.900 |
Why?
| Longitudinal Studies | 13 | 2024 | 2670 | 0.900 |
Why?
| Selenium | 2 | 2021 | 37 | 0.900 |
Why?
| Anti-Bacterial Agents | 5 | 2020 | 1702 | 0.890 |
Why?
| Insulin Resistance | 6 | 2022 | 1164 | 0.870 |
Why?
| Bacteria | 5 | 2023 | 812 | 0.870 |
Why?
| Infant Nutritional Physiological Phenomena | 3 | 2020 | 140 | 0.860 |
Why?
| Sugars | 1 | 2023 | 35 | 0.860 |
Why?
| Manganese | 2 | 2020 | 61 | 0.850 |
Why?
| Leg | 2 | 2015 | 241 | 0.830 |
Why?
| Risk Factors | 30 | 2022 | 9804 | 0.820 |
Why?
| Cross-Sectional Studies | 16 | 2025 | 5036 | 0.810 |
Why?
| Osteoporotic Fractures | 1 | 2023 | 58 | 0.810 |
Why?
| RNA, Ribosomal, 16S | 3 | 2024 | 521 | 0.790 |
Why?
| Blood Pressure Determination | 3 | 2019 | 150 | 0.770 |
Why?
| Diet, Mediterranean | 1 | 2022 | 27 | 0.770 |
Why?
| Body Composition | 3 | 2025 | 654 | 0.760 |
Why?
| Child, Preschool | 17 | 2025 | 10462 | 0.750 |
Why?
| Overweight | 10 | 2021 | 524 | 0.750 |
Why?
| Chorioamnionitis | 1 | 2021 | 38 | 0.740 |
Why?
| Birth Weight | 7 | 2024 | 494 | 0.730 |
Why?
| Hypotension | 1 | 2022 | 118 | 0.730 |
Why?
| Sex Hormone-Binding Globulin | 1 | 2020 | 53 | 0.710 |
Why?
| HTLV-I Infections | 9 | 2000 | 22 | 0.700 |
Why?
| Fats, Unsaturated | 1 | 2020 | 1 | 0.690 |
Why?
| Dietary Fats, Unsaturated | 1 | 2020 | 23 | 0.670 |
Why?
| Diet, Sodium-Restricted | 2 | 2019 | 36 | 0.670 |
Why?
| Weight Gain | 3 | 2018 | 504 | 0.660 |
Why?
| Body Fluids | 1 | 2019 | 61 | 0.660 |
Why?
| Flatulence | 1 | 2019 | 3 | 0.660 |
Why?
| Dyspepsia | 1 | 2019 | 10 | 0.650 |
Why?
| Androgens | 1 | 2020 | 173 | 0.640 |
Why?
| Cohort Studies | 13 | 2023 | 5400 | 0.620 |
Why?
| Pressure | 1 | 2020 | 238 | 0.620 |
Why?
| Abdominal Pain | 1 | 2020 | 145 | 0.610 |
Why?
| Vitamin D Deficiency | 1 | 2020 | 179 | 0.600 |
Why?
| Bayes Theorem | 5 | 2024 | 368 | 0.600 |
Why?
| Disinfectants | 1 | 2018 | 36 | 0.600 |
Why?
| Middle Aged | 37 | 2024 | 31024 | 0.590 |
Why?
| Boston | 6 | 2021 | 89 | 0.590 |
Why?
| Vitamin D | 2 | 2023 | 384 | 0.590 |
Why?
| Waist Circumference | 4 | 2016 | 137 | 0.590 |
Why?
| Estrogens | 1 | 2020 | 348 | 0.580 |
Why?
| Non-alcoholic Fatty Liver Disease | 1 | 2020 | 255 | 0.560 |
Why?
| Biomarkers | 5 | 2024 | 3878 | 0.560 |
Why?
| Skinfold Thickness | 2 | 2018 | 49 | 0.560 |
Why?
| Sequence Analysis, DNA | 1 | 2020 | 778 | 0.540 |
Why?
| Weight Loss | 5 | 2022 | 724 | 0.540 |
Why?
| Age Factors | 6 | 2020 | 3137 | 0.540 |
Why?
| Young Adult | 18 | 2021 | 12310 | 0.530 |
Why?
| Absorptiometry, Photon | 3 | 2025 | 249 | 0.520 |
Why?
| Puberty | 2 | 2014 | 143 | 0.520 |
Why?
| Gastrointestinal Tract | 2 | 2015 | 182 | 0.510 |
Why?
| Rural Population | 3 | 2018 | 504 | 0.510 |
Why?
| Singapore | 5 | 2013 | 20 | 0.500 |
Why?
| Adolescent | 23 | 2022 | 20241 | 0.490 |
Why?
| Infant Welfare | 1 | 2014 | 9 | 0.480 |
Why?
| Brazil | 7 | 2016 | 100 | 0.470 |
Why?
| Asthma | 3 | 2022 | 2260 | 0.470 |
Why?
| Leptin | 1 | 2016 | 217 | 0.470 |
Why?
| Abdominal Fat | 1 | 2014 | 40 | 0.460 |
Why?
| Health Status | 2 | 2023 | 750 | 0.450 |
Why?
| Adiponectin | 1 | 2016 | 232 | 0.450 |
Why?
| Metabolic Syndrome | 4 | 2021 | 339 | 0.440 |
Why?
| Intra-Abdominal Fat | 2 | 2024 | 89 | 0.430 |
Why?
| Baltimore | 2 | 2024 | 45 | 0.430 |
Why?
| Vitamins | 3 | 2024 | 173 | 0.430 |
Why?
| Chronic Disease | 1 | 2019 | 1717 | 0.430 |
Why?
| Inflammation | 1 | 2024 | 2696 | 0.430 |
Why?
| Diabetes, Gestational | 2 | 2018 | 306 | 0.430 |
Why?
| Feeding Behavior | 2 | 2017 | 621 | 0.430 |
Why?
| Glucose | 2 | 2015 | 976 | 0.420 |
Why?
| Dyslipidemias | 1 | 2015 | 176 | 0.420 |
Why?
| Linear Models | 6 | 2018 | 818 | 0.410 |
Why?
| Wrist | 1 | 2013 | 53 | 0.410 |
Why?
| Parity | 1 | 2013 | 120 | 0.410 |
Why?
| Fetal Development | 1 | 2016 | 283 | 0.410 |
Why?
| Social Class | 1 | 2015 | 256 | 0.410 |
Why?
| Anthropometry | 1 | 2013 | 205 | 0.410 |
Why?
| Aged | 21 | 2024 | 22068 | 0.400 |
Why?
| Fatty Liver | 1 | 2014 | 230 | 0.390 |
Why?
| Herpesvirus 4, Human | 5 | 1998 | 153 | 0.390 |
Why?
| Liver | 1 | 2020 | 1835 | 0.390 |
Why?
| Soy Foods | 1 | 2011 | 5 | 0.390 |
Why?
| Soybean Proteins | 1 | 2011 | 14 | 0.390 |
Why?
| Isoflavones | 1 | 2011 | 25 | 0.390 |
Why?
| Micronutrients | 2 | 2023 | 84 | 0.380 |
Why?
| Social Determinants of Health | 1 | 2015 | 215 | 0.380 |
Why?
| Environmental Pollutants | 2 | 2024 | 142 | 0.380 |
Why?
| Gestational Age | 3 | 2021 | 857 | 0.370 |
Why?
| Butyrates | 2 | 2022 | 53 | 0.360 |
Why?
| Obesity, Abdominal | 3 | 2016 | 46 | 0.360 |
Why?
| Time Factors | 7 | 2020 | 6579 | 0.340 |
Why?
| Intestinal Mucosa | 1 | 2015 | 570 | 0.340 |
Why?
| Bifidobacterium | 2 | 2021 | 21 | 0.340 |
Why?
| Probiotics | 2 | 2021 | 53 | 0.330 |
Why?
| Maternal Exposure | 2 | 2024 | 173 | 0.330 |
Why?
| Emigrants and Immigrants | 1 | 2012 | 120 | 0.330 |
Why?
| Child Health | 2 | 2023 | 146 | 0.330 |
Why?
| Protective Factors | 3 | 2019 | 91 | 0.310 |
Why?
| Papillomavirus Vaccines | 1 | 2012 | 229 | 0.310 |
Why?
| Follow-Up Studies | 8 | 2018 | 4927 | 0.310 |
Why?
| Socioeconomic Factors | 6 | 2021 | 1192 | 0.310 |
Why?
| Denmark | 2 | 2025 | 44 | 0.300 |
Why?
| Papillomavirus Infections | 1 | 2012 | 290 | 0.300 |
Why?
| Case-Control Studies | 7 | 2023 | 3336 | 0.300 |
Why?
| Beverages | 2 | 2023 | 67 | 0.300 |
Why?
| Prevalence | 10 | 2024 | 2541 | 0.290 |
Why?
| Women, Working | 2 | 2017 | 11 | 0.290 |
Why?
| Quality of Life | 1 | 2019 | 2711 | 0.280 |
Why?
| Logistic Models | 7 | 2023 | 1966 | 0.280 |
Why?
| Risk Assessment | 4 | 2020 | 3290 | 0.280 |
Why?
| Autism Spectrum Disorder | 2 | 2024 | 375 | 0.280 |
Why?
| Hodgkin Disease | 3 | 1998 | 136 | 0.270 |
Why?
| Incidence | 7 | 2022 | 2635 | 0.260 |
Why?
| Air Pollution | 2 | 2020 | 225 | 0.260 |
Why?
| Body Size | 2 | 2018 | 102 | 0.260 |
Why?
| Interviews as Topic | 3 | 2015 | 697 | 0.250 |
Why?
| Infant, Low Birth Weight | 2 | 2016 | 134 | 0.250 |
Why?
| Sleep | 2 | 2023 | 657 | 0.250 |
Why?
| Emergency Medical Services | 1 | 2012 | 562 | 0.240 |
Why?
| Quebec | 1 | 2025 | 10 | 0.240 |
Why?
| Blood Glucose | 5 | 2021 | 2088 | 0.240 |
Why?
| Pregnancy Complications | 3 | 2024 | 487 | 0.240 |
Why?
| Pregnancy Trimester, First | 2 | 2024 | 133 | 0.230 |
Why?
| Infectious Mononucleosis | 2 | 1998 | 9 | 0.230 |
Why?
| Folic Acid | 3 | 2024 | 182 | 0.230 |
Why?
| Fecal Microbiota Transplantation | 1 | 2024 | 18 | 0.230 |
Why?
| Bacteroides fragilis | 1 | 2024 | 13 | 0.230 |
Why?
| Diet, Vegetarian | 1 | 2024 | 7 | 0.230 |
Why?
| Ohio | 2 | 2015 | 153 | 0.230 |
Why?
| Biometry | 1 | 2024 | 68 | 0.220 |
Why?
| Chemokine CCL2 | 1 | 2024 | 122 | 0.220 |
Why?
| Homeostasis | 3 | 2016 | 605 | 0.220 |
Why?
| Research Design | 2 | 2021 | 1039 | 0.220 |
Why?
| Antibodies, Viral | 6 | 1991 | 599 | 0.220 |
Why?
| Oligosaccharides | 1 | 2024 | 57 | 0.220 |
Why?
| Kynurenine | 1 | 2024 | 103 | 0.220 |
Why?
| Vitamin A | 1 | 2023 | 56 | 0.210 |
Why?
| Severity of Illness Index | 3 | 2020 | 2768 | 0.210 |
Why?
| Mucus | 1 | 2024 | 74 | 0.210 |
Why?
| Metals | 1 | 2024 | 126 | 0.210 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 1264 | 0.210 |
Why?
| Nutrition Assessment | 2 | 2015 | 85 | 0.210 |
Why?
| Maternal Age | 1 | 2023 | 121 | 0.210 |
Why?
| Tryptophan | 1 | 2024 | 168 | 0.210 |
Why?
| Cannabidiol | 1 | 2024 | 88 | 0.210 |
Why?
| Aging | 2 | 2024 | 1773 | 0.210 |
Why?
| Dronabinol | 1 | 2024 | 166 | 0.200 |
Why?
| Phthalic Acids | 1 | 2022 | 44 | 0.200 |
Why?
| Sodium, Dietary | 2 | 2019 | 41 | 0.200 |
Why?
| Pancreatic Neoplasms | 1 | 2010 | 878 | 0.190 |
Why?
| District of Columbia | 3 | 2021 | 26 | 0.190 |
Why?
| Epidemiologic Studies | 1 | 2022 | 66 | 0.190 |
Why?
| Anti-Infective Agents | 1 | 2024 | 246 | 0.190 |
Why?
| Sodium | 2 | 2021 | 205 | 0.190 |
Why?
| Obesity Management | 1 | 2021 | 8 | 0.190 |
Why?
| Registries | 2 | 2024 | 1916 | 0.190 |
Why?
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2021 | 39 | 0.190 |
Why?
| Regression Analysis | 3 | 2012 | 987 | 0.190 |
Why?
| Glycemic Index | 1 | 2021 | 25 | 0.190 |
Why?
| Permeability | 1 | 2022 | 158 | 0.190 |
Why?
| Purines | 1 | 2022 | 170 | 0.190 |
Why?
| Cardiovascular System | 1 | 2023 | 138 | 0.180 |
Why?
| Sex Characteristics | 2 | 2016 | 724 | 0.180 |
Why?
| Clostridium perfringens | 1 | 2021 | 5 | 0.180 |
Why?
| Clostridium | 1 | 2021 | 14 | 0.180 |
Why?
| Bacteroides | 1 | 2021 | 19 | 0.180 |
Why?
| Oxides | 1 | 2021 | 41 | 0.180 |
Why?
| Observational Studies as Topic | 1 | 2021 | 108 | 0.180 |
Why?
| Smoking | 4 | 2013 | 1501 | 0.180 |
Why?
| Growth | 1 | 2021 | 58 | 0.180 |
Why?
| Health Impact Assessment | 1 | 2020 | 8 | 0.180 |
Why?
| Minority Groups | 1 | 2022 | 240 | 0.170 |
Why?
| Odds Ratio | 6 | 2023 | 1021 | 0.170 |
Why?
| Models, Statistical | 1 | 2024 | 627 | 0.170 |
Why?
| Uric Acid | 1 | 2021 | 158 | 0.170 |
Why?
| Postpartum Period | 1 | 2023 | 332 | 0.170 |
Why?
| DNA, Ribosomal | 1 | 2020 | 81 | 0.170 |
Why?
| Dysbiosis | 1 | 2021 | 166 | 0.170 |
Why?
| Massachusetts | 1 | 2020 | 159 | 0.170 |
Why?
| Skin Absorption | 1 | 2019 | 12 | 0.170 |
Why?
| HTLV-I Antibodies | 4 | 1992 | 5 | 0.170 |
Why?
| Vulnerable Populations | 1 | 2021 | 155 | 0.170 |
Why?
| Interdisciplinary Research | 1 | 2020 | 26 | 0.170 |
Why?
| Appetite | 1 | 2020 | 57 | 0.170 |
Why?
| Sex Factors | 4 | 2019 | 1950 | 0.160 |
Why?
| Digestive System | 1 | 2019 | 30 | 0.160 |
Why?
| Hepatitis C | 2 | 2000 | 234 | 0.160 |
Why?
| Mercury | 1 | 2019 | 39 | 0.160 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2024 | 1204 | 0.160 |
Why?
| Cadmium | 1 | 2019 | 67 | 0.160 |
Why?
| Cholesterol, HDL | 1 | 2020 | 203 | 0.160 |
Why?
| Lead | 1 | 2019 | 55 | 0.160 |
Why?
| Insulin-Like Growth Factor I | 1 | 2021 | 308 | 0.160 |
Why?
| Venezuela | 1 | 2018 | 7 | 0.160 |
Why?
| United States | 8 | 2023 | 13992 | 0.160 |
Why?
| Behavior Therapy | 1 | 2021 | 236 | 0.160 |
Why?
| Men's Health | 1 | 2018 | 7 | 0.160 |
Why?
| Employment | 2 | 2017 | 162 | 0.160 |
Why?
| United States Food and Drug Administration | 1 | 2019 | 204 | 0.150 |
Why?
| Age Distribution | 2 | 2018 | 377 | 0.150 |
Why?
| DNA, Bacterial | 1 | 2020 | 324 | 0.150 |
Why?
| Dizziness | 1 | 2019 | 80 | 0.150 |
Why?
| Health Status Disparities | 1 | 2021 | 242 | 0.150 |
Why?
| Nutritional Status | 2 | 2024 | 325 | 0.150 |
Why?
| Age of Onset | 2 | 2016 | 494 | 0.150 |
Why?
| Lipopolysaccharides | 1 | 2022 | 877 | 0.150 |
Why?
| Skin | 1 | 2023 | 737 | 0.150 |
Why?
| Surveys and Questionnaires | 4 | 2014 | 5365 | 0.150 |
Why?
| Cholesterol, LDL | 1 | 2020 | 360 | 0.140 |
Why?
| Public Health | 2 | 2021 | 493 | 0.140 |
Why?
| Infant, Small for Gestational Age | 1 | 2018 | 83 | 0.140 |
Why?
| Pregnancy Complications, Cardiovascular | 1 | 2018 | 80 | 0.140 |
Why?
| Nutrition Surveys | 2 | 2021 | 259 | 0.140 |
Why?
| Reference Values | 1 | 2019 | 791 | 0.140 |
Why?
| Computational Biology | 1 | 2021 | 588 | 0.140 |
Why?
| Leukocytes | 1 | 2018 | 301 | 0.140 |
Why?
| Verrucomicrobia | 1 | 2016 | 5 | 0.140 |
Why?
| Liver Neoplasms | 2 | 2000 | 637 | 0.140 |
Why?
| Colombia | 2 | 2016 | 37 | 0.140 |
Why?
| Clinical Trials as Topic | 2 | 2019 | 1005 | 0.130 |
Why?
| Developing Countries | 2 | 2017 | 278 | 0.130 |
Why?
| Income | 1 | 2017 | 191 | 0.130 |
Why?
| Confidence Intervals | 2 | 2012 | 318 | 0.130 |
Why?
| Death | 1 | 2017 | 124 | 0.130 |
Why?
| Phylogeny | 1 | 2020 | 844 | 0.130 |
Why?
| Particulate Matter | 1 | 2018 | 249 | 0.130 |
Why?
| Aspartame | 1 | 2015 | 3 | 0.130 |
Why?
| Preconception Care | 1 | 2016 | 39 | 0.120 |
Why?
| Pandemics | 2 | 2021 | 1516 | 0.120 |
Why?
| Epidemiologic Methods | 2 | 2013 | 75 | 0.120 |
Why?
| Intestines | 1 | 2018 | 347 | 0.120 |
Why?
| Coffee | 1 | 2015 | 15 | 0.120 |
Why?
| Japan | 4 | 2000 | 100 | 0.120 |
Why?
| Animals | 7 | 2024 | 34708 | 0.120 |
Why?
| Caffeine | 1 | 2015 | 62 | 0.120 |
Why?
| Nutrition Policy | 1 | 2015 | 56 | 0.120 |
Why?
| China | 1 | 2015 | 187 | 0.120 |
Why?
| Elective Surgical Procedures | 1 | 2016 | 164 | 0.120 |
Why?
| Dietary Supplements | 3 | 2024 | 533 | 0.120 |
Why?
| Child Nutritional Physiological Phenomena | 1 | 2015 | 105 | 0.120 |
Why?
| Organ Size | 1 | 2015 | 446 | 0.120 |
Why?
| Body Weight | 1 | 2019 | 936 | 0.120 |
Why?
| Proportional Hazards Models | 2 | 2022 | 1221 | 0.110 |
Why?
| California | 1 | 2015 | 402 | 0.110 |
Why?
| Prognosis | 2 | 2019 | 3793 | 0.110 |
Why?
| Immunoglobulin M | 3 | 1991 | 268 | 0.110 |
Why?
| Physical Examination | 1 | 2015 | 238 | 0.110 |
Why?
| Oxidative Stress | 1 | 2019 | 1221 | 0.100 |
Why?
| Glucose Metabolism Disorders | 1 | 2012 | 11 | 0.100 |
Why?
| Diabetic Angiopathies | 1 | 2014 | 263 | 0.100 |
Why?
| Multivariate Analysis | 2 | 2017 | 1504 | 0.100 |
Why?
| Central America | 1 | 2012 | 21 | 0.100 |
Why?
| South America | 1 | 2012 | 56 | 0.100 |
Why?
| Capsid Proteins | 2 | 1991 | 90 | 0.100 |
Why?
| Analysis of Variance | 1 | 2015 | 1285 | 0.100 |
Why?
| Abdomen | 1 | 2012 | 116 | 0.100 |
Why?
| Area Under Curve | 1 | 2012 | 286 | 0.100 |
Why?
| Brain | 1 | 2023 | 2604 | 0.090 |
Why?
| Demography | 3 | 2017 | 280 | 0.090 |
Why?
| Lymphoma, Non-Hodgkin | 1 | 1991 | 78 | 0.090 |
Why?
| Antigens, Viral | 3 | 1999 | 181 | 0.090 |
Why?
| ROC Curve | 1 | 2012 | 501 | 0.090 |
Why?
| Immunoglobulin G | 3 | 1991 | 837 | 0.090 |
Why?
| Cytokines | 1 | 2018 | 1997 | 0.090 |
Why?
| Occupations | 3 | 2017 | 42 | 0.080 |
Why?
| Dietary Sucrose | 1 | 2010 | 47 | 0.080 |
Why?
| Uterine Cervical Neoplasms | 1 | 2012 | 233 | 0.080 |
Why?
| Diabetes Mellitus | 2 | 2016 | 991 | 0.080 |
Why?
| Mice | 2 | 2024 | 16583 | 0.080 |
Why?
| Health Promotion | 1 | 2015 | 713 | 0.080 |
Why?
| Treatment Outcome | 2 | 2021 | 10256 | 0.080 |
Why?
| Epidemiology | 1 | 2008 | 15 | 0.070 |
Why?
| Predictive Value of Tests | 1 | 2013 | 1968 | 0.070 |
Why?
| India | 2 | 2021 | 167 | 0.070 |
Why?
| Hypoglycemic Agents | 1 | 2016 | 1208 | 0.070 |
Why?
| Patient Selection | 1 | 2011 | 671 | 0.070 |
Why?
| Cytomegalovirus | 1 | 1988 | 156 | 0.070 |
Why?
| Smoking Cessation | 1 | 2011 | 409 | 0.070 |
Why?
| Testicular Neoplasms | 1 | 1988 | 102 | 0.070 |
Why?
| Human T-lymphotropic virus 1 | 2 | 1999 | 28 | 0.070 |
Why?
| Nucleoside-Triphosphatase | 1 | 2006 | 6 | 0.060 |
Why?
| RNA Helicases | 1 | 2006 | 24 | 0.060 |
Why?
| Flavivirus | 1 | 2006 | 17 | 0.060 |
Why?
| Lipids | 2 | 2022 | 616 | 0.060 |
Why?
| Waist-Hip Ratio | 2 | 2016 | 36 | 0.060 |
Why?
| Viral Nonstructural Proteins | 1 | 2006 | 58 | 0.060 |
Why?
| Muscle, Skeletal | 1 | 2015 | 1629 | 0.060 |
Why?
| Tomography, X-Ray Computed | 1 | 2014 | 2530 | 0.060 |
Why?
| Binomial Distribution | 1 | 2024 | 5 | 0.060 |
Why?
| Health Services Accessibility | 1 | 2012 | 894 | 0.060 |
Why?
| Spatial Analysis | 1 | 2024 | 21 | 0.060 |
Why?
| Georgia | 1 | 2024 | 79 | 0.060 |
Why?
| Insulin | 3 | 2021 | 2313 | 0.060 |
Why?
| Retrospective Studies | 3 | 2018 | 14562 | 0.050 |
Why?
| Vegetables | 1 | 2023 | 146 | 0.050 |
Why?
| Heartburn | 1 | 2021 | 12 | 0.050 |
Why?
| Maryland | 1 | 2021 | 43 | 0.050 |
Why?
| Nutritional Requirements | 1 | 2021 | 77 | 0.050 |
Why?
| Hunger | 1 | 2021 | 38 | 0.050 |
Why?
| Iron | 1 | 2023 | 285 | 0.050 |
Why?
| Gout | 1 | 2021 | 36 | 0.050 |
Why?
| American Heart Association | 1 | 2023 | 311 | 0.050 |
Why?
| City Planning | 1 | 2020 | 1 | 0.040 |
Why?
| Africa, Eastern | 1 | 2020 | 11 | 0.040 |
Why?
| Transportation | 1 | 2020 | 52 | 0.040 |
Why?
| Causality | 1 | 2020 | 115 | 0.040 |
Why?
| Cities | 1 | 2020 | 104 | 0.040 |
Why?
| Capital Financing | 1 | 2020 | 7 | 0.040 |
Why?
| Child Development | 1 | 2024 | 451 | 0.040 |
Why?
| Tuberculin | 1 | 1999 | 8 | 0.040 |
Why?
| Double-Blind Method | 1 | 2024 | 1864 | 0.040 |
Why?
| Personal Satisfaction | 1 | 2021 | 198 | 0.040 |
Why?
| Lipoproteins, HDL | 1 | 2019 | 85 | 0.040 |
Why?
| Mentoring | 1 | 2021 | 120 | 0.040 |
Why?
| Meconium | 1 | 2018 | 7 | 0.040 |
Why?
| Lipoproteins, LDL | 1 | 2019 | 131 | 0.040 |
Why?
| Viral Matrix Proteins | 1 | 1998 | 25 | 0.040 |
Why?
| Oncogene Proteins, Viral | 1 | 1998 | 22 | 0.040 |
Why?
| Aged, 80 and over | 5 | 1997 | 7063 | 0.040 |
Why?
| Th1 Cells | 1 | 1999 | 135 | 0.040 |
Why?
| Diet, Western | 1 | 2019 | 79 | 0.040 |
Why?
| Environmental Exposure | 1 | 2022 | 479 | 0.040 |
Why?
| Virus Latency | 1 | 1998 | 90 | 0.040 |
Why?
| Pregnancy Trimester, Third | 1 | 2018 | 105 | 0.040 |
Why?
| Metabolic Diseases | 1 | 2018 | 106 | 0.040 |
Why?
| Cholesterol | 1 | 2019 | 400 | 0.040 |
Why?
| Sex Distribution | 2 | 2014 | 358 | 0.040 |
Why?
| Immunologic Memory | 1 | 1999 | 337 | 0.030 |
Why?
| Calcium | 1 | 2023 | 1175 | 0.030 |
Why?
| Triglycerides | 1 | 2019 | 519 | 0.030 |
Why?
| Cancer Survivors | 1 | 2021 | 260 | 0.030 |
Why?
| Sarcoma, Kaposi | 1 | 1997 | 75 | 0.030 |
Why?
| Mucins | 1 | 2016 | 71 | 0.030 |
Why?
| Deltaretrovirus Antibodies | 1 | 1996 | 1 | 0.030 |
Why?
| Nutritional Physiological Phenomena | 1 | 2016 | 52 | 0.030 |
Why?
| Health Care Costs | 1 | 2019 | 404 | 0.030 |
Why?
| Health Behavior | 1 | 2021 | 733 | 0.030 |
Why?
| Pregnancy Outcome | 1 | 2018 | 379 | 0.030 |
Why?
| Environmental Monitoring | 1 | 2018 | 333 | 0.030 |
Why?
| Health Surveys | 1 | 2017 | 486 | 0.030 |
Why?
| Ambulatory Care | 1 | 2019 | 509 | 0.030 |
Why?
| Disease Transmission, Infectious | 1 | 1996 | 56 | 0.030 |
Why?
| Databases, Factual | 1 | 2021 | 1289 | 0.030 |
Why?
| Carrier State | 1 | 1996 | 60 | 0.030 |
Why?
| Educational Status | 1 | 2017 | 458 | 0.030 |
Why?
| Dominican Republic | 1 | 2015 | 21 | 0.030 |
Why?
| RNA, Viral | 1 | 1998 | 622 | 0.030 |
Why?
| New York | 1 | 2015 | 127 | 0.030 |
Why?
| Gene Products, tax | 2 | 1991 | 13 | 0.030 |
Why?
| Body Fat Distribution | 1 | 2014 | 49 | 0.030 |
Why?
| Hyperlipidemias | 1 | 2015 | 124 | 0.030 |
Why?
| Hepatitis B | 1 | 1995 | 62 | 0.030 |
Why?
| Glucose Tolerance Test | 1 | 2015 | 356 | 0.030 |
Why?
| Poverty | 1 | 2017 | 492 | 0.030 |
Why?
| Communication | 1 | 2020 | 839 | 0.030 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2019 | 1367 | 0.030 |
Why?
| Epstein-Barr Virus Nuclear Antigens | 2 | 1991 | 10 | 0.030 |
Why?
| Colorado | 1 | 2023 | 4445 | 0.030 |
Why?
| Carcinoma, Hepatocellular | 1 | 1995 | 267 | 0.030 |
Why?
| Sensitivity and Specificity | 1 | 2017 | 1842 | 0.030 |
Why?
| Serologic Tests | 1 | 1992 | 49 | 0.020 |
Why?
| Forestry | 1 | 1992 | 4 | 0.020 |
Why?
| Fisheries | 1 | 1992 | 3 | 0.020 |
Why?
| Leukemia, T-Cell | 1 | 1991 | 4 | 0.020 |
Why?
| DNA | 1 | 2018 | 1407 | 0.020 |
Why?
| Toxoplasmosis | 1 | 1992 | 37 | 0.020 |
Why?
| Hyperglycemia | 1 | 2015 | 321 | 0.020 |
Why?
| Nasopharyngeal Neoplasms | 1 | 1991 | 16 | 0.020 |
Why?
| Paraparesis, Tropical Spastic | 1 | 1991 | 3 | 0.020 |
Why?
| Leukemia-Lymphoma, Adult T-Cell | 1 | 1991 | 13 | 0.020 |
Why?
| Capsid | 1 | 1991 | 89 | 0.020 |
Why?
| Agriculture | 1 | 1992 | 91 | 0.020 |
Why?
| Reproducibility of Results | 1 | 2018 | 3047 | 0.020 |
Why?
| Hospitalization | 1 | 2019 | 2080 | 0.020 |
Why?
| Sexually Transmitted Diseases | 1 | 1991 | 146 | 0.020 |
Why?
| Dysgerminoma | 1 | 1988 | 6 | 0.020 |
Why?
| Immunoglobulin A | 1 | 1989 | 190 | 0.020 |
Why?
| United Kingdom | 1 | 2008 | 264 | 0.020 |
Why?
| Science | 1 | 2008 | 53 | 0.020 |
Why?
| Teratoma | 1 | 1988 | 102 | 0.020 |
Why?
| Neoplasms | 1 | 2021 | 2429 | 0.020 |
Why?
| History, 20th Century | 1 | 2008 | 295 | 0.020 |
Why?
| Risk | 1 | 1989 | 867 | 0.020 |
Why?
| Phenotype | 1 | 2014 | 3062 | 0.020 |
Why?
| Molecular Sequence Data | 2 | 2006 | 2846 | 0.020 |
Why?
| Health Personnel | 1 | 1992 | 643 | 0.020 |
Why?
| Sequence Homology, Amino Acid | 1 | 2006 | 370 | 0.020 |
Why?
| Virus Replication | 1 | 1987 | 448 | 0.010 |
Why?
| Recombinant Proteins | 2 | 1999 | 1306 | 0.010 |
Why?
| Amino Acid Sequence | 1 | 2006 | 2050 | 0.010 |
Why?
| Tritium | 1 | 1999 | 74 | 0.010 |
Why?
| Thymidine | 1 | 1999 | 58 | 0.010 |
Why?
| Mycobacterium bovis | 1 | 1999 | 16 | 0.010 |
Why?
| BCG Vaccine | 1 | 1999 | 24 | 0.010 |
Why?
| Interleukin-12 | 1 | 1999 | 118 | 0.010 |
Why?
| Antigens, Bacterial | 1 | 1999 | 120 | 0.010 |
Why?
| Blotting, Western | 2 | 1991 | 1189 | 0.010 |
Why?
| Interleukin-2 | 1 | 1999 | 428 | 0.010 |
Why?
| Cell Division | 1 | 1999 | 802 | 0.010 |
Why?
| Greece | 1 | 1997 | 7 | 0.010 |
Why?
| Interferon-gamma | 1 | 1999 | 759 | 0.010 |
Why?
| Acquired Immunodeficiency Syndrome | 1 | 1997 | 226 | 0.010 |
Why?
| Hepatitis Antibodies | 1 | 1995 | 1 | 0.010 |
Why?
| Hepatitis B Surface Antigens | 1 | 1995 | 19 | 0.010 |
Why?
| Otorhinolaryngologic Diseases | 1 | 1995 | 14 | 0.010 |
Why?
| Hepatitis B virus | 1 | 1995 | 34 | 0.010 |
Why?
| Seroepidemiologic Studies | 1 | 1995 | 155 | 0.010 |
Why?
| Eye Diseases | 1 | 1995 | 78 | 0.010 |
Why?
| Hepacivirus | 1 | 1995 | 235 | 0.010 |
Why?
| Life Style | 1 | 1995 | 459 | 0.010 |
Why?
| Blood Transfusion | 1 | 1995 | 294 | 0.010 |
Why?
| Retroviruses, Simian | 1 | 1991 | 1 | 0.010 |
Why?
| HTLV-I Antigens | 1 | 1991 | 1 | 0.010 |
Why?
| Genes, pX | 1 | 1991 | 2 | 0.010 |
Why?
| Papio | 1 | 1991 | 97 | 0.010 |
Why?
| Cells, Cultured | 1 | 1999 | 4063 | 0.010 |
Why?
| Agglutination Tests | 1 | 1991 | 4 | 0.010 |
Why?
| Radioimmunoprecipitation Assay | 1 | 1990 | 6 | 0.010 |
Why?
| Radioimmunoassay | 1 | 1991 | 169 | 0.010 |
Why?
| Lymphocytes | 1 | 1991 | 369 | 0.010 |
Why?
| DNA, Viral | 1 | 1991 | 380 | 0.010 |
Why?
| Antibody Formation | 1 | 1991 | 284 | 0.010 |
Why?
| Polymerase Chain Reaction | 1 | 1991 | 1045 | 0.000 |
Why?
| Alcohol Drinking | 1 | 1995 | 742 | 0.000 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 1990 | 822 | 0.000 |
Why?
| Base Sequence | 1 | 1991 | 2157 | 0.000 |
Why?
| Family | 1 | 1991 | 651 | 0.000 |
Why?
| Postoperative Complications | 1 | 1995 | 2497 | 0.000 |
Why?
|
|
Mueller's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|